New study of nearly 4,000 people of African ancestries led to identification of gene inhibiting HIV replication.
Features
July 17, 2023
Taking place in Brisbane, Australia, this International AIDS Society (IAS) conference features the latest scientific research for progress aga...
Germany commits to 9.2 million Euros for the next five years to support development of a safe, effective, affordable, and accessible tuberculo...
Sequential immunization approach used furthers IAVI’s HIV vaccine development.
June 29, 2023
Wellcome and Gates Foundation announce plans to fund a Phase III clinical trial of the tuberculosis vaccine candidate M72 in adults.
This series of articles in PharmacoEconomics are designed to map evidence gaps and identify health economic research priorities for the HIV pr...
June 6, 2023
The first episode of Meet The Scientist, IAVI’s new podcast series, will explore the importance of economic modeling for TB vaccine R&D ...
New analysis of IAVI G001 trial shows nanoparticle HIV vaccine creates strong immune response in helper T cells.
Expanded access would benefit many in low- and middle-income countries.
April 28, 2023
IAVI Board member and ICAP founder Wafaa El-Sadr recognized for her contributions to global health.
March 30, 2023
Presentations will focus on vaccines for HIV, neglected diseases, and pandemic preparedness.
Show More
Media Contacts
North America
Rose Catlos
+1 212 847 1049
RCatlos@iavi.org
